NCT07884669Not yet recruiting
Biomarker Investigation for Early Gastric Cancer Detection
Biomarker Investigation for Early Gastric Cancer Detection: a Prospective Study in Gastric and Gastroesophageal Junction Adenocarcinomas (G/GEJ)
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
GASTROTRACK is a prospective, single-center clinico-biological cohort study evaluating non-invasive biomarkers for gastric and gastroesophageal junction adenocarcinomas (GEC). Saliva, gastric juice, plasma, and tumor tissue samples will be collected from patients undergoing upper gastrointestinal endoscopy. The study aims to identify molecular and microbial biomarkers associated with cancer diagnosis. Disease monitoring and relapse risk will be evaluated through integration of blood- and tissue-based analyses.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 1 Oct 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 30 Nov 2028
- Lead sponsor
- Centre Leon Berard
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07884669
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Nov 2026 to the primary completion date, 30 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- E1. Patients with known active malignancy. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.
- E2. Patients with known genetic predisposition such as Lynch syndrome or hereditary diffuse gastric cancer.
- E3. Any condition contraindicating any procedure required by the protocol.
Other
- E4. Patients presenting a psychological, familial, geographical, or social situation that, in the investigator's judgment, could potentially prevent the signing of informed consent and/or compliance with study procedures.
- E5. Pregnant or breast-feeding women.
Who the study is looking for
- I1. Patients ≥ 18 years at the day of signing informed consent.
- I2. Patients referred for upper gastrointestinal endoscopy due to upper GI symptoms such as dysphagia, unexplained anemia, persistent dyspepsia or melena or following initial GEC diagnosis in another institution.
- I3. Patients who have understood, dated, and signed the written voluntary informed consent form.
- I4. Patients affiliated with or benefiting from medical insurance.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.